[Indianapolis, IN] — January 20, 2026 — Aria announced the in-house validation of an oral fluid toxicology panel designed to support clinical settings where traditional urine collection is impractical or inappropriate. The new offering reflects a “right test, right patient” approach, enabling providers to select the most suitable testing approach based on patient context and care setting realities.
Oral fluid collection reduces operational constraints and eliminates the need for restroom facilities. Testing can be performed in a directly observed, privacy-preserving manner by all levels of clinical staff. These attributes make it well-suited for behavioral health programs, telehealth-supported visits, mobile clinics, and patients with limited mobility or barriers to urine production.
The confirmatory oral fluid panel is performed in-house and includes all CMS drug classes with 42 regionally relevant drugs commonly encountered in pain management and behavioral health settings. Processing the test internally at the Indianapolis-based laboratory guarantees industry-leading turnaround times while maintaining the analytical rigor providers require.
“Oral fluid testing expands access to drug monitoring in settings where urine collection isn’t feasible or appropriate,” said Vipin Adhlakha, Owner of Aria Diagnostics. “Our clinical focus is on supporting providers and laboratory partners with reliable testing options that fit real-world care models.”
Aria’s oral fluid testing is available now to both provider clients and laboratory partners seeking a reliable reference solution that complements existing toxicology testing services.